Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors | Zendy

George D. Demetri | Zendy; Margaret von Mehren | Zendy; Charles D. Blanke | Zendy; Annick D. Van den Abbeele | Zendy; Burton Eisenberg | Zendy; Peter Roberts‎ | Zendy; Michael C. Heinrich | Zendy; David A. Tuveson | Zendy; Samuel Singer | Zendy; Milos J. Janicek | Zendy; Jonathan A. Fletcher | Zendy; Stuart G. Silverman | Zendy; Sandra Silberman | Zendy; Renaud Capdeville | Zendy; Beate Kiese | Zendy; Bin Peng | Zendy; Saša Dimitrijević | Zendy; Brian J. Druker | Zendy; Christopher L. Corless | Zendy; Christopher D.�M. Fletcher | Zendy; Heikki Joensuu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors

Author(s) -

George D. Demetri,

Margaret von Mehren,

Charles D. Blanke,

Annick D. Van den Abbeele,

Burton Eisenberg,

Peter Roberts‎,

Michael C. Heinrich,

David A. Tuveson,

Samuel Singer,

Milos J. Janicek,

Jonathan A. Fletcher,

Stuart G. Silverman,

Sandra Silberman,

Renaud Capdeville,

Beate Kiese,

Bin Peng,

Saša Dimitrijević,

Brian J. Druker,

Christopher L. Corless,

Christopher D.�M. Fletcher,

Heikki Joensuu

Publication year - 2002

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa020461

Subject(s) - medicine , imatinib , imatinib mesylate , tyrosine kinase inhibitor , tolerability , gastroenterology , sunitinib , myeloid leukemia , clinical trial , tyrosine kinase , oncology , adverse effect , pharmacology , cancer , receptor

Constitutive activation of KIT receptor tyrosine kinase is critical in the pathogenesis of gastrointestinal stromal tumors. Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclinical models and preliminary clinical studies to have activity against such tumors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research